TeraImmune proudly announces that its application for translational, IND-enabling cell manufacturing services and regulatory support for FVIII TCR-engineered Treg cells was approved by the National Heart, Lung, and Blood Institute (NHLBI). The project Task Order was awarded on 29 May 2019 to the following PACT Cell Processing Facility: Moffitt Cancer Center.
